Aktis Oncology prices IPO at $18 per share

[IPO Initial Public Offering text, inscription. IPO concept, banner. 3D render]
bin kontan

* Aktis Oncology (AKTS [https://seekingalpha.com/symbol/AKTS]) priced [https://seekingalpha.com/pr/20358916-aktis-oncology-announces-pricing-of-its-upsized-initial-public-offering] its upsized initial public offering at $18 per share, raising approximately $318M.
* Aktis develops targeted radiopharmaceuticals using a miniprotein platform for oncology, targeting tumors like Nectin-4 across multiple cancers.
* The underwriters have a 30-day option to purchase up to an additional ~2.65M shares at the IPO price.
* Trading under the ticker "AKTS" begins today, January 9, 2026, on the Nasdaq.
* The offering is expected to close on January 12.
* J.P. Morgan, BofA Securities, Leerink Partners and TD Cowen are acting as joint book-running managers for the offering.

MORE ON AKTIS ONCOLOGY

* Aktis Oncology Pursues $200 Million IPO On Promising Early Stage Studies [https://seekingalpha.com/article/4857466-aktis-oncology-pursues-200-million-ipo-on-promising-early-stage-studies]
* Lilly partner Aktis targets up to $840M valuation in U.S. IPO [https://seekingalpha.com/news/4536821-lilly-partner-aktis-targets-840m-value-ipo]
* Lilly-backed radiopharma startup Aktis seeks U.S. IPO [https://seekingalpha.com/news/4534618-lilly-backed-radiopharma-startup-aktis-seeks-us-ipo]
* Seeking Alpha’s Quant Rating on Aktis Oncology, Inc. [https://seekingalpha.com/symbol/AKTS/ratings/quant-ratings]
* Financial information for Aktis Oncology, Inc. [https://seekingalpha.com/symbol/AKTS/income-statement]